|
KMID : 0941820220320030178
|
|
Korean Journal of Clinical Pharmacy
2022 Volume.32 No. 3 p.178 ~ p.184
|
|
|
Medication Prescribing Status in Pediatric Patients with Migraine
|
|
Rhew Ki-Yon
|
|
|
Abstract
|
|
|
Background: Migraine is one of the leading causes of poor quality of life and disability, and migraine incidences in pediatrics areincreasing. Proper medication is important for the preventive and acute treatment of migraine. This study aimed to identify thecurrent status of prescribed medication in pediatric patients with migraine.
Methods: We used data from a sample of pediatric patientsfrom the Health Insurance Review and Assessment Service (HIRA-PPS-2018) and analyzed the status of prescription drugs andfrequency of visits to medical institutions with migraine diagnoses in pediatric patients.
Results: A total of 12,228 pediatric patientsdiagnosed with migraine during 2018 were analyzed. Among these patients, 7,170 (58.64%) were girls and 9,510 (77.77%) wereadolescents. Additionally, 9,157 patients (74.89%) received acute treatment, and 592 patients (4.84%) received combination therapywith analgesics and triptans. Acetaminophen for acute treatment and flunarizine for preventive treatment were the most commonlyprescribed. In most children and adolescents, acute treatment drugs were prescribed for less than 14 days.
Conclusion: Analgesics,such as acetaminophen or non-steroidal anti-inflammatory drugs, were prescribed frequently for acute treatment in pediatric patientswith migraine. The drug prescription duration was within the recommended range, indicating a low risk of overdose. For preventivetreatment, clinically studied medication for pediatric patients with migraine was used.
|
|
|
KEYWORD
|
|
|
Migraine, pediatrics, analgesics, triptans
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|